Meissa's Positive Clinical Data for the First RSV Vaccine …
https://www.meissavaccines.com/post/meissa-s-positive-clinical-data-for-the-first-rsv-vaccine-designed-to-protect-infants-toddlers
WEBREDWOOD CITY, Calif., August 8, 2023 – Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced positive safety and immunogenicity data for MV-012-968, Meissa’s intranasal live attenuated RSV vaccine candidate, from a clinical study in RSV-naïve ...
DA: 5 PA: 91 MOZ Rank: 61